Diamyd Inc, Pittsburgh, PA, USA.
Pain Med. 2009 Oct;10(7):1325-30. doi: 10.1111/j.1526-4637.2009.00720.x.
The first human trial of gene therapy for chronic pain, a phase 1 study of a nonreplicating herpes simplex virus (HSV)-based vector engineered to express preproenkephalin in patients with intractable pain from cancer, began enrolling subjects in December 2008. In this article, we describe the rationale underlying this potential approach to treatment of pain, the preclinical animal data in support of this approach, the design of the study, and studies with additional HSV-based vectors that may be used to develop treatment for other types of pain.
首例慢性疼痛基因治疗的人体临床试验，是对一种非复制型单纯疱疹病毒（HSV）载体的 1 期研究，该载体经过基因工程改造后能在癌症导致的顽固性疼痛患者中表达前原脑啡肽。这项临床试验于 2008 年 12 月开始招募受试者。本文介绍了这种治疗疼痛的潜在方法的基本原理、支持这种方法的临床前动物数据、研究设计以及其他 HSV 载体的研究，这些研究可能用于开发治疗其他类型疼痛的方法。
